A non-steroidal anti-inflammatory drug (NSAID), for the treatment of postoperative ocular inflammation following cataract extraction, has been approved for use in the European market by the European Commission.
A non-steroidal anti-inflammatory drug (NSAID), for the treatment of postoperative ocular inflammation following cataract extraction, has been approved for use in the European market by the European Commission.
Yellox, owned by CROMA, is to be administered twice daily as an ocular NSAID in adult patients after undergoing cataract surgery. Otherwise known as, Yellox (bromfenac sodium) targets the COX-2 enzyme- one of the prime causes of prostaglandin production and ocular inflammation. The solution penetrates through the cornea and ocular tissues to treat ocular inflammation.
CROMA will collaborate with Bausch+Lomb to promote the ophthalmic solution in Austria, France, Spain, Poland and Romania. Bausch+Lomb will manage promotions in the remaining EU countries.
Chief Medical Officer of Bausch+Lomb, Dr Cal Roberts, said: “Yellox is very promising for cataract surgery patients. The drug helps meet the unmet needs of both patients and physicians alike across a number of European markets, offering them a new choice to treat post-operative ocular inflammation following cataract extraction.”
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.